Androgen substitution treatment (ART), frequently refered to as testosterone substitution treatment (TRT), is a type of chemical treatment, wherein androgens, frequently testosterone, are supplanted. In order to combat the effects of male hypogonadism, ART is frequently prescribed. Typically, testosterone is administered via injection, skin cream, patch, gel, or subcutaneous pellet form. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.
Market Dynamics
The androgen replacement therapy market is expected to witness growth during the forecast period, owing to the increasing mergers and acquisitions among pharmaceutical companies. For instance, in October 2022, Tolmar Inc., a U.S-based pharmaceutical research, development, manufacturing and commercial operations company, announced the acquisition of all rights to JATENZO, an oral softgel testosterone medicine from Clarus Therapeutics Holdings, Inc. and its wholly-owned subsidiary Clarus Therapeutics, Inc.- a pharmaceutical company with specialization in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. following a public auction.
Key features of the study:
- This report provides an in-depth analysis of global androgen replacement therapy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global androgen replacement therapy market based on the following parameters– company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include AbbVie, Inc., Bayer AG, Endo International plc, Lilly, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Clarus Therapeutics, Perrigo Company plc, Acerus Pharmaceuticals Corporation, Sawai Pharmaceutical Co.,Ltd, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., and Simple Pharma.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global androgen replacement therapy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global androgen replacement therapy market
Detailed Segmentation:
- Global Androgen Replacement Therapy Market, By Product Type:
- Testosterone Creams/Gels
- Testosterone Patches
- Testosterone Injections
- Testosterone Implants
- Testosterone Tablets/Capsules/Gums
- Global Androgen Replacement Therapy Market, By Active Ingredient :
- Testosterone
- Methyl Testosterone
- Testosterone Undecanoate
- Testosterone Enanthate
- Testosterone Cypionate
- Global Androgen Replacement Therapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Androgen Replacement Therapy Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AbbVie, Inc.
- Bayer AG
- Endo International plc
- Lilly
- Kyowa Kirin Co., Ltd.
- Novartis AG
- Pfizer Inc
- Clarus Therapeutics
- Perrigo Company plc
- Acerus Pharmaceuticals Corporation
- Sawai Pharmaceutical Co.,Ltd
- Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- Simple Pharma
